Skip to main content

Table 3 Prognostic factors for overall survival in the eribulin arm

From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review

Variables n HR 95 % CI P value
Lung metastasis 27 0.90 0.42–1.95 0.79
Liver metastasis 36 1.25 0.56–2.78 0.59
Bone metastasis 43 1.42 0.58–3.50 0.44
CNS metastasis 9 1.36 0.44–4.17 0.59
Other metastasis 47 0.46 0.20–1.02 0.06
Anthracycline-based regimen for EBC 21 0.51 0.15–1.73 0.28
Anthracycline-based regimen for MBC 24 0.36 0.11–0.83 0.02*
Taxane-based regimen for EBC 13 0.48 0.08–2.77 0.41
Taxane-based regimen for MBC 41 0.66 0.22–1.96 0.45
Eribulin as first-/second-line for MBC 31 0.90 0.37–2.20 0.82
Taxane-based regimen prior to eribulin 28 1.41 0.63–3.14 0.40
Duration of eribulin treatment >median (125 days) 33 0.45 0.21–0.94 0.03*
  1. CI confidence interval, CNS central nervous system, EBC early breast cancer, HR hazard ratio, MBC metastatic breast cancer